These treatments utilize ACE inhibitors and angiotensin receptor blockers, and they involve the activation of the RAS's protective arm with MasR agonist (Ang-(1-7)), (ii) ACE2-based treatments, and (iii) the protective effect of alamandine on COVID-19 patients, because of its anti-inflammatory, antifibrotic, and antioxidative properties. Here, ACE2 is linked to COVID-19.